K-Bio Value Report

[카테고리:] Biosimilar

  • Celltrion vs. Samsung Bioepis: Which One Holds the Global Edge?

    For everyday investors, choosing between South Korea’s two biotech titans—Celltrion and Samsung Bioepis—often feels like choosing between a “pioneering architect” and a “master manufacturer.” As of 2026, while both are global leaders, Celltrion is currently perceived to have a higher level of strategic global competitiveness for three key reasons. 1. The “Zymfentra” Effect: Beyond Copycats…

  • Samsung Bioepis

    Samsung Bioepis

    The Shift from “First Mover” to “Smart Follower” and Innovation In 2026, Samsung Bioepis is executing a dual-track strategy: stabilizing its massive biosimilar engine while navigating a more complex competitive landscape where “speed” is being challenged by “utility” (formulation). 1. Commercial Footprint: 11 Products and the “Direct Sales” Leap As of early 2026, Samsung Bioepis…